首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1475233

全球支原體診斷市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Mycoplasma Diagnostics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 218 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球支原體診斷市場需求預計將從 2023 年的 19.8 億美元達到近 40 億美元的市場規模，2024 年至 2032 年研究期間複合年成長率為 8.12%。

支原體診斷是指用於檢測和識別支原體種類的實驗室測試和方法，支原體是一組可以感染人類、植物和動物的細菌。細胞培養、生物製藥、疫苗和其他生物製品中的支原體污染可能會損害研究的完整性、產品品質和安全性，因此準確可靠的診斷至關重要。支原體檢測方法可能包括基於培養的技術、聚合酶鏈反應 (PCR)、酶聯免疫吸附測定 (ELISA)、DNA 染色和核酸擴增測試 (NAAT)。

市場動態

人類和動物支原體感染的盛行率不斷增加，以及人們對這些感染相關潛在健康風險的認知不斷提高，推動了對準確可靠的診斷測試的需求。眾所周知，支原體可引起多種呼吸系統、泌尿生殖系統和全身性疾病，因此及時且準確的診斷對於採取適當的治療和感染控制措施至關重要。此外，由於對傳染病快速且準確診斷的需求，臨床環境中對現場護理和快速診斷測試的需求不斷成長，推動了支原體診斷檢測的開發和商業化。此外，分子和血清學檢測技術的進步，例如聚合酶鏈反應（PCR）、酶聯免疫吸附測定（ELISA）和核酸擴增檢測（NAAT），提高了支原體診斷檢測的靈敏度、特異性和周轉時間，改善患者治療效果並降低醫療成本。

此外，由於控制家畜和伴侶動物支原體感染的需要，支原體診斷在獸醫和畜牧業實踐中擴大採用，有助於市場成長。由於支原體感染對農業和水產養殖業造成重大經濟損失，對準確有效的診斷工具來管理這些感染的需求持續成長。此外，新型支原體物種和抗生素抗藥性菌株的出現進一步強調了不斷創新和開發支原體診斷方法以應對不斷變化的診斷挑戰的重要性。然而，替代診斷技術和新測試方法的進步可能會在未來幾年挑戰支原體診斷市場的成長，因為這些創新可以提供更快、更具成本效益或更準確的診斷解決方案。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球支原體診斷市場的每個細分市場進行了包容性評估。支原體診斷產業的成長和趨勢為本研究提供了整體方法。

市場區隔

支原體診斷市場報告的這一部分提供了國家和區域級別細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。

按產品分類

試劑盒和試劑
儀器
軟體與服務

依技術

聚合酶鍊式反應
免疫測定（ELISA、RIA）
DNA染色
微生物培養技術
其他

按最終用戶

醫院
診斷實驗室
診所
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲支原體診斷市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。支原體診斷市場的主要參與者包括 Merck & Co., Inc.、F. Hoffmann-La Roche AG、Agilent Technologies、Sartorius AG、Savyon Diagnostics、Takara Bio Inc.（Takara Holding Company Inc.）、Lonza Group、Charles River Laboratories International, Inc.、Thermo Fisher Scientific Inc.、PromoCell GmbH。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：支原體診斷公司的競爭格局

支原體診斷市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Merck & Co. Inc.

公司簡介
公司收入
產品
最近的發展

F. Hoffmann-La Roche AG

公司簡介
公司收入
產品
最近的發展

Agilent Technologies

公司簡介
公司收入
產品
最近的發展

Sartorius AG

公司簡介
公司收入
產品
最近的發展

Savyon Diagnostics

公司簡介
公司收入
產品
最近的發展

Takara Bio Inc. (Takara Holding Company Inc.)

公司簡介
公司收入
產品
最近的發展

Lonza Group

公司簡介
公司收入
產品
最近的發展

Charles River Laboratories International Inc.

公司簡介
公司收入
產品
最近的發展

Thermo Fisher Scientific Inc.

公司簡介
公司收入
產品
最近的發展

PromoCell GmbH

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114318

The global demand for Mycoplasma Diagnostics Market is presumed to reach the market size of nearly USD 4 Billion by 2032 from USD 1.98 Billion in 2023 with a CAGR of 8.12% under the study period 2024 - 2032.

Mycoplasma diagnostics refers to laboratory tests and methods used to detect and identify mycoplasma species, a group of bacteria that can infect humans, plants, and animals. Mycoplasma contamination in cell cultures, biopharmaceuticals, vaccines, and other biological products can compromise research integrity, product quality, and safety, making accurate and reliable diagnostics essential. Mycoplasma detection methods may include culture-based techniques, polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), DNA staining, and nucleic acid amplification tests (NAATs).

MARKET DYNAMICS

The increasing prevalence of mycoplasma infections in humans and animals and the rising awareness of the potential health risks associated with these infections drive the demand for accurate & reliable diagnostic tests. Mycoplasma species are known to cause a wide range of respiratory, genitourinary, and systemic diseases, making timely and accurate diagnosis essential for appropriate treatment and infection control measures. Additionally, the growing demand for point-of-care and rapid diagnostic tests in clinical settings, driven by the need for quick and accurate diagnosis of infectious diseases, fuels the development and commercialization of mycoplasma diagnostic assays. Moreover, advancements in molecular and serological testing technologies, such as polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and nucleic acid amplification tests (NAATs), enhance the sensitivity, specificity, and turnaround time of mycoplasma diagnostic tests, improving patient outcomes and reducing healthcare costs.

Furthermore, the increasing adoption of mycoplasma diagnostics in veterinary medicine and animal husbandry practices, driven by the need to control mycoplasma infections in livestock and companion animals, contributes to market growth. With mycoplasma infections posing significant economic losses in the agriculture and aquaculture industries, the demand for accurate & efficient diagnostic tools to manage these infections continues to rise. Moreover, the emergence of novel mycoplasma species and antibiotic-resistant strains further underscores the importance of continuously innovating and developing mycoplasma diagnostics to address evolving diagnostic challenges. However, advancements in alternative diagnostic technologies and new testing methods may challenge the mycoplasma diagnostics market growth in the coming years, as these innovations could offer faster, more cost-effective, or more accurate diagnostic solutions.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of mycoplasma diagnostics. The growth and trends of mycoplasma diagnostics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the mycoplasma diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Kits & Reagents
Instruments
Software & Services

By Technology

PCR
Immunoassay (ELISA, RIA)
DNA Staining
Microbial Culture Techniques
Others

By End-User

Hospitals
Diagnostic Laboratories
Clinics
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Mycoplasma Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Mycoplasma Diagnostics market include Merck & Co., Inc., F. Hoffmann-La Roche AG, Agilent Technologies, Sartorius AG, Savyon Diagnostics, Takara Bio Inc. (Takara Holding Company Inc.), Lonza Group, Charles River Laboratories International, Inc., Thermo Fisher Scientific Inc., PromoCell GmbH. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. MYCOPLASMA DIAGNOSTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Technology
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data
5.3. Analysis By Product
5.4. Kits & Reagents Historic and Forecast Sales By Regions
5.5. Instruments Historic and Forecast Sales By Regions
5.6. Software & Services Historic and Forecast Sales By Regions

6. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY TECHNOLOGY

6.1. Overview By Technology
6.2. Historical and Forecast Data
6.3. Analysis By Technology
6.4. PCR Historic and Forecast Sales By Regions
6.5. Immunoassay (ELISA, RIA) Historic and Forecast Sales By Regions
6.6. DNA Staining Historic and Forecast Sales By Regions
6.7. Microbial Culture Techniques Historic and Forecast Sales By Regions
6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY END-USER

7.1. Overview By End-user
7.2. Historical and Forecast Data
7.3. Analysis By End-user
7.4. Hospitals Historic and Forecast Sales By Regions
7.5. Diagnostic Laboratories Historic and Forecast Sales By Regions
7.6. Clinics Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE MYCOPLASMA DIAGNOSTICS COMPANIES

9.1. Mycoplasma Diagnostics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF MYCOPLASMA DIAGNOSTICS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Merck & Co. Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. F. Hoffmann-La Roche AG
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Agilent Technologies
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Sartorius AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Savyon Diagnostics
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Takara Bio Inc. (Takara Holding Company Inc.)
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Lonza Group
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Charles River Laboratories International Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Thermo Fisher Scientific Inc.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. PromoCell GmbH
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments